Development Track of Compliance With Dual Antiplatelet Therapy and Analysis of Potential Categories in Patients With ACS After PCI.

BACKGROUND

To explore the potential categories of compliance development track of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) using growth mixture modeling (GMM) to analyze its predictive factors, providing evidence for dynamic adherence monitoring and tailored interventions.

METHODS

A total of 150 patients with ACS after PCI were selected by convenience sampling. Patients were studied using Self-Efficacy for Appropriate Medication Use Scale (SEAMS), family APGAR index (APGAR), Generalized Anxiety Disorder-2 (GAD-2), and Patient Health Questionnaire-2 (PHQ-2) at baseline. The compliance of patients with DAPT was assessed using Morisky Medication Adherence Scales-8 (MMAS-8) at 1, 3, 6, 9, and 12 months after discharge. The mixed model of latent variable growth was used to identify the development track of compliance. Multiple logistic regression was used to analyze the predictive factors of different development track categories.

RESULTS

Two development track categories of DAPT compliance in patients with ACS after PCI were identified in the low compliance-decreased group (7.41%) and the persistent high compliance group (92.59%). Multivariate logistic regression analysis showed that age ≥60 years, body mass index (BMI), and the family APGAR index were the predictive factors of different development track categories of DAPT compliance in patients with ACS after PCI.

CONCLUSION

Significant population heterogeneity was observed in the development track of DAPT in ACS patients within 12 months after PCI. The compliance of most patients remained stable, and only a few remained at a low level and showed a significant downward trend. Based on these predictive factors, healthcare personnel can identify patients in the low compliance-decreased group early and implement targeted and specific interventions to improve DAPT compliance of ACS patients after PCI.